Form D · Biotechnology

PAINREFORM LTD.

Tel Aviv, L3 · CIK 0001801834

Offering snapshot reported Mar 19, 2021 · SEC filing

Reported sold
$6M
Offering amount: $6M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 8, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 19, 2021Initial$6,000,000No comparison3SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$390K
Finders' fees
$0
Form D file number
021-392928
The shares, warrants and shares underlying the warrants were issued in connection with an offering of (i) 1,304,346 ordinary shares and (ii) warrants to purchase up to an aggregate of 652,173 ordinary shares.
Maxim Group LLC is entitled to 6.5% of the gross proceeds of the offering, $40,000 expense reimbursement and warrants to purchase 52,173 ordinary shares exercisable for $5.06 for five years.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Maxim Group LLC120708

Source: Form D, filed Mar 19, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Ellen Baron Director
Efi Cohen Arazi Director
Ehud Geller Director, Executive
Ilan Hadar Director, Executive
Eli Hazum Director
Augustine Lawlor Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
4 Bruria St.
Tel Aviv, L3, 6745442